21st Mar 2016 07:52
LONDON (Alliance News) - Hutchison China MediTech Ltd on Monday said its Hutchison MediPharma Ltd subsidiary has started a phase 3 registration trial of sulfatinib in China in patients with pancreatic neuroendocrine tumours.
The trial will be a randomised, double-blind, placebo-controlled study to treat patients with low or intermediate-grade neuroendocrine tumours, Hutchison said.
Around 195 patients will take part, with the top-line results from the study expected in 2018.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed